tradmap

JBIO Earnings Jade Biosciences, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$15 -$7 $0 2021 2022 2023 2024 2025
EPS
Net income (annual)
-$127M -$64M $0 2020 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-69% 40% 149% 0% 2020 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$12 -$6 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$56M -$28M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-26% 2090% 4206% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–20 of 20
Q2 20262026-06-30-1.332026-08-1010-Q
Q1 20262026-03-31-0.572026-05-0710-Q
FY 20252025-12-31-3.192026-03-0610-K
Q3 20252025-09-30-3.082025-11-1410-Q
Q2 20262025-06-30-3.452026-08-1010-Q
Q1 20262025-03-31-12.102026-05-0710-Q
FY 20252024-12-31-14.892026-03-0610-K
Q3 20252024-09-30-5.352025-11-1410-Q
Q2 20252024-06-30-0.192025-08-1310-Q
Q1 20252024-03-31-0.832025-04-2510-Q
FY 20242023-12-31-2.872025-03-2710-K
Q3 20242023-09-30-2.132024-11-1210-Q
Q2 20242023-06-30-1.422024-08-1210-Q
Q1 20242023-03-31-0.672024-05-1310-Q
FY 20232022-12-31-2.102024-03-2510-K
Q3 20232022-09-30-1.492023-11-1310-Q
Q2 20232022-06-30-0.942023-08-1410-Q
Q1 20232022-03-31-0.452023-05-1510-Q
FY 20222021-12-31-1.872023-03-2910-K
Q3 20222021-09-30-1.802022-11-1410-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.